A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
about
Gastric biomarkers: a global reviewReview on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor TreatmentMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerMolecular markers: Implications for cytopathology and specimen collectionThe advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loopEngineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapyEvaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signalingEfficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathwayImmune Therapy in GI Malignancies: A Review.Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance.Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells.Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis.Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer.miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.RUNX1 positively regulates the ErbB2/HER2 signaling pathway through modulating SOS1 expression in gastric cancer cells.Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy.[Current biomarkers for gastric cancer].
P2860
Q26741859-3AB72FE8-8D4D-43DD-B737-318F69FCDC91Q27009539-E5C2AFEC-AB2F-4331-935D-0BC324DE49C9Q28072513-E93B77FA-F39D-4DD9-9B1A-D0F9B3DBC103Q28087155-A12B4313-2E6C-41FB-B3FF-2A4A1004A4CAQ34648886-9940B3B7-602C-4409-A5BE-3246BD90B980Q35741610-F4DCD70A-2201-4FE0-8C19-D181554CE552Q35746919-4A7BC34A-B28D-47B6-AAE6-28E91C1C3881Q37001973-1EF3FE0B-D49C-4AC6-83E5-65B89B72BB02Q37124053-0EE94B80-8BCB-458A-8097-FBE1DF7EB68DQ37580446-A834648E-5E5F-49C3-8F5F-FE3B8CD21BA9Q37652251-0F02D437-16E8-4904-85AB-9473143A57C0Q38445709-B145F87C-9265-48AB-9A33-145396524FB7Q38703402-9089094B-0A52-4D84-8B29-092319EF51C4Q38780521-2ED3A46B-CBBA-4851-9EC7-15026169F6F4Q38849205-91CB6FE4-A621-4F17-BE49-643275C33E99Q38853156-1ECFDE81-436D-4197-BA73-D097E7804EF6Q38856729-D14C1271-93E8-48BC-9273-4D48C47DB86DQ47425148-05EE2F1D-13C8-4826-8B8C-1C3B99BCEFC9Q47838777-E3F069F4-8010-4C7E-99DC-95B059F24027Q48379063-FF02020F-A400-4AFF-A623-93E03A8794CEQ48549971-BFE6A507-4ADB-4D91-863E-2D9E1AFBFCECQ50417171-F2A111F6-D6FF-41AC-B17F-20468C15C0E9Q52568539-49A911AE-6711-483A-95F7-1DFE7143FE37Q53223448-C3006894-5E48-476B-907A-5EAA77481740Q53496282-0E0DFA78-D710-474B-86EF-2B01AA25CC10
P2860
A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
A critical review of HER2-posi ...... from trastuzumab, and beyond.
@en
type
label
A critical review of HER2-posi ...... from trastuzumab, and beyond.
@en
prefLabel
A critical review of HER2-posi ...... from trastuzumab, and beyond.
@en
P2093
P50
P1433
P1476
A critical review of HER2-posi ...... from trastuzumab, and beyond.
@en
P2093
Carlos Gomez-Martín
Fernando Lopez-Rios
Fernando Rivera
Florian Lordick
Jorge Aparicio
Mercedes Salgado
Roberto Pazo
P356
10.1016/J.CANLET.2014.05.019
P407
P577
2014-06-03T00:00:00Z